From a patient’s perspective, things have never looked brighter. Never before have more drugs been under development. With access to better healthcare, patients are now driving unrealistic expectations on biopharma in the new landscape of real world outcomes data and governments demanding cuts in healthcare bills.
How do payers and biopharma build new relationships to manage costs and drive innovation and jobs into the future? Dr Christoph Schnorr, Vice President at Quintiles Drug Development Consulting, has 30 years of technical and operational expertise in health care and in particular research & development in the biopharmaceutical industry. He will share real insights around:
Rapidly changing Healthcare marketplace
View of R&D in the future
Creating direct-to-patient programs & clinical data networks
How will direct patient involvement pay-off
What does the future of personalized medicine hold
In the fast-changing healthcare environment, where payers are under pressure to cut costs, technology can bring patients closer to research programmes resulting in better outcomes for all. But will these new relationships require a re-think in how biopharma works with its stakeholders of governments, payers & physicians and what does that look like in the future?
Only if Biopharma can be efficient in developing beneficial partnerships with its stakeholders will it get the completive edge to be successful in the future.
Date: 30 May 2013
Time: 08:30 – 10:00
Venue: Room: Stavanger
Address: Arne Jacobsens Allé 15, DK-2300 Copenhagen S